Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 6Terminated 4Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Prostatic Neoplasms 5Breast Neoplasms 4Prostate Adenocarcinoma 1Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Trastuzumab 77Capecitabine 59Cyclophosphamide 54Paclitaxel 51Docetaxel 49Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 25exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Everolimus 17Taxes 16Epirubicin 15Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13pertuzumab 12palbociclib 12liposomal doxorubicin 11Magnetic Resonance Spectroscopy 11Filgrastim 11Cisplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Triptorelin Pamoate × Clear all
NCT02113553 2022-09-10

Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve

Istituto Clinico Humanitas

Phase 2 Terminated
45 enrolled
Breast

Breast Neoplasms

NCT00090844 2021-01-28

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

University of South Florida

Phase 2 Terminated
49 enrolled 10 charts
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT00194792 2017-07-11

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

University of Washington

Phase 2 Terminated
28 enrolled 9 charts
Breast

Breast Neoplasms

NCT00066807 2016-10-28

PERCHE

ETOP IBCSG Partners Foundation

Phase 3 Terminated
29 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡